{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-012731","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.452832+00:00","generated_at":"2026-05-23T08:17:21.302170+00:00","sec_items":["1.01","2.03","2.01","2.02","8.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catheter Precision acquires heart failure device assets; Q1 revenue up 73% to $142k","bullets":["Subsidiary Cardionomix buys patents/trademarks for Cardionomic's CPNS System (acute decompensated heart failure).","Purchase price: 1M restricted VTAK shares plus a $1.5M promissory note (4% interest, 3-year maturity).","Closing conditions include NYSE American listing approval; deal must close by July 21, 2025.","Preliminary Q1 2025 revenue $142k vs $82k YoY (+73%).","Company warns it needs additional financing to develop assets; dilution expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-012731","json":"https://secwatch.observer/filing/0001437749-25-012731.json","markdown":"https://secwatch.observer/filing/0001437749-25-012731.md","text":"https://secwatch.observer/filing/0001437749-25-012731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925012731/0001437749-25-012731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925012731/vtak20250415_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:17:21.302170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dde266bf4759dee3538e3ec1c67d5308ac556c0f","claim":"Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing three years following issuance.","evidence_excerpt":"the issuance by Cardionomix of a promissory note (the \"Note\") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be three years following issuance of the Note.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925012731/0001437749-25-012731-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$1.5 million"},{"label":"Counterparty","value":"Cardionomic (assignment for the benefit of creditors), LLC"},{"label":"Rate","value":"4% per annum"},{"label":"Maturity","value":"three years following issuance"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}